You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SUPERCONDUCTING MAGNET FOR MICROCOIL NMR
SBC: American Magnetics, Inc. Topic: N/ADESCRIPTION (Verbatim from the Applicant's Abstract): The specific aims of this Phase I STTR project, proposed by the American Magnetics, Inc. in partnership with the MIT Francis Bitter Magnet Laboratory, are: 1) experimental demonstration of feasibility of innovative design and operation features applicable to NMR Nb3Sn-magnet/cryocooler systems; and 2) co ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
Gene Expression and Diagnosis of Autoimmune Disease
SBC: ARTHROCHIP, LLC Topic: N/ADESCRIPTION (provided by the applicant): Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, and multiple sclerosis, are thought to arise from abnormalities of innate or adaptive immune responses. Autoimmune diseases are often difficult to diagnose, as the symptoms can be typical of other conditions and quite vague, such as musculoskeletal complaints ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Gene Expression and Diagnosis of Autoimmune Disease
SBC: ARTHROCHIP, LLC Topic: N/ADESCRIPTION (provided by applicant): Autoimmune diseases are thought to arise from abnormalities in innate or adaptive immune responses and most likely have both genetic and environmental components. Diagnosis of autoimmune disease is often difficult, as t he symptoms can be relatively nonspecific. Furthermore, no available blood test can accurately exclude the possibility of an autoimmune disease ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Gene Expression and Diagnosis of Diabetes
SBC: ARTHROCHIP, LLC Topic: N/ADESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be typical of other conditions and quite vague. No currently available blood test accurately excludes or includes the possibility of an autoimmune disease in a subject, and a battery of tests and a period of observation are usually required. A single test that could readily distinguish between ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Gene Expression and Diagnosis of Diabetes
SBC: ARTHROCHIP, LLC Topic: N/ADESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be nonspecific. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes mellitus (DM), which has two subsets, Type I and Type II. The sub ...
STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
PPMP as a Ceramide Catabolism Inhibitor for Chemotherapy
SBC: AVANTI POLAR LIPIDS, INC. Topic: N/ADESCRIPTION (provided by applicant): Our goal is to develop 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) as a clinical inhibitor of ceremide catabolism, in order to enhance the anti-cancer activity of the cytotoxic retinoid, fenretinide (4-HPR). We have reported that 4-HPR increased ceramide in numerous pediatric and adult solid cancer and leukemia cell lines in vitro. We have also ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Optimal Hydrophobicity of Lipoid Gene Delivery Agents
SBC: AVANTI POLAR LIPIDS, INC. Topic: N/ADESCRIPTION (provided by applicant): Cationic lipid-like compounds are commonly used in vitro and in vivo to deliver DNA to cells for the purposes of expressing exogenous genes. A number of clinical trials have indicated the promise of these agents for gene therapy, however lipid-based delivery remains less effective than the alternative viral vectors. Nevertheless, vast improvements have been mad ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Novel Reagents to Bypass Limitations of Existing Coagulation Assays
SBC: AVANTI POLAR LIPIDS, INC. Topic: N/ADESCRIPTION (provided by applicant): We propose to identify an optimal short carbon chain lipid species to be used as a surrogate for membranes in a novel and improved blood coagulation factor assays that will improve rapid diagnosis of coagulation disorders. Blood coagulation protects the integrity of damaged blood vessels and is localized specifically to cells at a site of injury by exposure of ...
STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
Antiatherogenic Properties of tert-Butylhydroquinone
SBC: BIOINVENTIONS, LLC Topic: N/ADESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
TGF-beta for Pleurodesis
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pleural effusion (MPE). This fluid impairs breathing and worsens the quality of life in these patients. The current treatments are not ideal and include removing the fluid by repetitive needle aspiratio ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health